Current treatment for hypertension, dyslipidemia, and diabetes was recorded as a binary status, whereas specific drug classes (e.g., β-blockers, calcium-channel blockers, ACE inhibitors/ARBs, diuretics, insulin, SGLT2 inhibitors, GLP-1 receptor agonists, statins), doses, and treatment duration were not available. This evidence concerns the gene SLC5A2 and metabolic syndrome.